FDA Classifies CFTR Gene Mutation Detection Systems into Class II Special Controls

Summary

The FDA is classifying cystic fibrosis transmembrane conductance regulator (CFTR) gene mutation detection systems into class II (special controls) to ensure the safety and effectiveness of these devices, with a guidance document titled 'Class II Special Controls Guidance Document: CFTR Gene Mutation Detection Systems' available for public review.